Investor Presentation - Asia Dengue Summit
Filed with ASX · · 16 pages · English
Summary by 6ix AI
Island Pharmaceuticals Ltd has released an investor presentation for the Asia Dengue Summit, detailing new data from the PROTECT study. The company is advancing discussions with potential partners for further clinical trials based on these encouraging findings.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Island Pharmaceuticals Ltd on 6ix
In the deck
Story so far
Earlier from Island Pharmaceuticals
- Investor presentation
- Island Secures USAMRIID Support for Galidesivir Study
- Island Advances Galidesivir GMP Manufacturing for Biodefence
- Island Adds Biodefence Leader as Filovirus Risks Escalate
- Island Bolsters US Biodefence Readiness Ahead of Trials
Later from Island Pharmaceuticals
- FDA Grants Orphan Designation for Galidesivir in Marburg
- Singapore Patent Expands Island's ISLA 101 Viral Protection
- Pause in Trading
- Galidesivir approved for treatment use in in Ebola epidemic
- Investor Presentation - Ebola Clinical Program
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals